LeonaBio (LONA) vs Pelthos Therapeutics (PTHS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
LeonaBio (LONA) has outperformed Pelthos Therapeutics (PTHS) over the past year, losing 56.1% versus a loss of 74.9%. LeonaBio is the larger company by market cap ($26.4 million vs $25.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LONA | PTHS |
|---|---|---|
| Share price | $2.02 | $6.38 |
| Market cap | $26.41M | $25.08M |
| 1-day change | -17.89% | -8.73% |
| YTD return | -73.32% | -79.42% |
| 1-year return | -56.13% | -74.88% |
| 5-year return | -98.55% | — |
| EPS (TTM) | $-22.20 | $-23.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $16.80M |
| Net income (latest FY) | $-105.61M | $-43.32M |
| Gross margin | — | 76.25% |
| Operating margin | — | -193.09% |
| Net margin | — | -257.93% |
| 52-week high | $14.21 | $31.62 |
| 52-week low | $1.91 | $6.02 |
| Distance from 52-week high | -85.78% | -79.82% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +757.92% | +732.92% |
| Average volume | 195.37K | 54.38K |
| Shares outstanding | 13.08M | 3.93M |
| Employees | 19 | 92 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LONA has outperformed PTHS by 18.7 percentage points over the past year.
About LeonaBio
LONA stock →LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company's lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 19 employees
About Pelthos Therapeutics
PTHS stock →Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 92 employees
LONA vs PTHS FAQ
Which is bigger, LeonaBio or Pelthos Therapeutics?
LeonaBio (LONA) is larger, with a market capitalization of $26.41M compared with $25.08M for Pelthos Therapeutics (PTHS).
Which stock has performed better over the past year, LONA or PTHS?
LONA returned -56.13% over the past 12 months, compared with -74.88% for PTHS (price return, excluding dividends). Past performance does not predict future results.
Are LeonaBio and Pelthos Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.